Quintica

National Comprehensive Cancer Network | October 16, 2020

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2). The research funding is supported by a $2-million grant from Puma Biotechnology, Inc. Projects may include pre-clinical, translational and clinical trials. They will focus on treatment of: ...

MedTech

Evaxion Biotech | July 04, 2022

The clinical-stage biotechnology company Evaxion Biotech A/S which specializes in the creation of AI-driven immunotherapies, said today that it has chosen gonorrhea as its second bacterial target for the Company's EVX-B2 vaccine product candidate. Evaxion has opted to create a preventative vaccination against Gonorrhea, a sexually transmitted disease (STD) that has fast acquired antibiotic resistance, as its second bacterial target. Based on preliminary results in pre-clinical...

MedTech

TheraVet SA | September 19, 2022

TheraVet a pioneering company in the management of osteoarticular diseases in pets, announced today its participation in the annual congress of the European Society of Veterinary Orthopaedics and Traumatology which will be held from 21 to 24 September at the Acropolis in Nice, France. With nearly 1000 participants, this event is the largest specialised congress in veterinary orthopaedics and traumatology in Europe, bringing together high-quality international speakers and therefor...

Industrial Impact

Arctic Vision | July 05, 2022

Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced that the first patient has been enrolled in a Phase III clinical study evaluating ARVN003, a proprietary pilocarpine formulation leveraging its micro dosing platform Optejet®, as a treatment to temporarily improve vision in adults with presbyopia in China. The Phase III study is double-masked, placebo-controlled, randomized, and multicenter trial evaluating the efficacy and safet...